Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib

The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-...

Full description

Saved in:
Bibliographic Details
Published in:Rare tumors 2016-06, Vol.8 (2), p.6266-89
Main Authors: Mahuad, Carolina Valeria, Repáraz, María de Los Ángeles Vicente, Zerga, Marta E, Aizpurua, María Florencia, Casali, Claudia, Garate, Gonzalo
Format: Article
Language:English
Subjects:
anaplastic
anaplastic lymphoma kinase
Case Report
crizotinib
large-cell
Lymphoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-competitive inhibitor for ALK, approved for its use in lung cancer with rearrangements on ALK gene. The reported cases describe the use of crizotinib as a bridging strategy prior to allotransplantation; there are no reported prolonged survivals under monotherapy with Crizotinib. We report a case of a primary refractory ALK+ anaplastic large-cell lymphoma that sustains complete response after 3 years of crizotinib monotherapy.
ISSN:2036-3605
2036-3613
2036-3613
DOI:10.4081/rt.2016.6266